Chemical strategies to overcome resistance against targeted anticancer therapeutics
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Authors
Keywords
-
Journal
Nature Chemical Biology
Volume 16, Issue 8, Pages 817-825
Publisher
Springer Science and Business Media LLC
Online
2020-07-22
DOI
10.1038/s41589-020-0596-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Designing a chemical inhibitor for the AAA protein spastin using active site mutations
- (2019) Tommaso Cupido et al. Nature Chemical Biology
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- Targeted protein degradation: elements of PROTAC design
- (2019) Stacey-Lynn Paiva et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
- (2019) Tyler B. Faust et al. Nature Chemical Biology
- Covalent Small Molecules as Enabling Platforms for Drug Discovery
- (2019) Samuel E. Dalton et al. CHEMBIOCHEM
- Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
- (2019) Dirksen E. Bussiere et al. Nature Chemical Biology
- CRISPR Approaches to Small Molecule Target Identification
- (2018) Marco Jost et al. ACS Chemical Biology
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- A Convergence-Based Framework for Cancer Drug Resistance
- (2018) David J. Konieczkowski et al. CANCER CELL
- Spectrum and functional validation of PSMB5 mutations in multiple myeloma
- (2018) Santiago Barrio et al. LEUKEMIA
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes
- (2018) Jasper Edgar Neggers et al. Nature Communications
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
- (2018) Khyati N. Shah et al. NATURE MEDICINE
- Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
- (2017) W Qiang et al. LEUKEMIA
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
- (2017) Kyuho Han et al. NATURE BIOTECHNOLOGY
- Selective degradation of splicing factor CAPERα by anticancer sulfonamides
- (2017) Taisuke Uehara et al. Nature Chemical Biology
- Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis
- (2017) Jonathan J. Ipsaro et al. PLoS One
- CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy
- (2017) Leyuan Ma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
- (2017) Ting Han et al. SCIENCE
- Leveraging Chemotype-Specific Resistance for Drug Target Identification and Chemical Biology
- (2017) Tarun M. Kapoor et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer
- (2017) Andrew Dhawan et al. Scientific Reports
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- Toward a Better Understanding of the Complexity of Cancer Drug Resistance
- (2016) Michael M. Gottesman et al. Annual Review of Pharmacology and Toxicology
- Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
- (2016) Boyang Zhao et al. CELL
- Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
- (2016) E. Ardini et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
- (2015) D. Ercan et al. CLINICAL CANCER RESEARCH
- Differential DNA mismatch repair underlies mutation rate variation across the human genome
- (2015) Fran Supek et al. NATURE
- Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
- (2015) Junwei Shi et al. NATURE BIOTECHNOLOGY
- The ins and outs of selective kinase inhibitor development
- (2015) Susanne Müller et al. Nature Chemical Biology
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Multidrug evolutionary strategies to reverse antibiotic resistance
- (2015) M. Baym et al. SCIENCE
- Viral quasispecies
- (2015) Raul Andino et al. VIROLOGY
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets
- (2014) Corynn Kasap et al. Nature Chemical Biology
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
- (2014) Philip P Chamberlain et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
- (2014) Nikhil Wagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation pathway of Src kinase reveals intermediate states as targets for drug design
- (2014) Diwakar Shukla et al. Nature Communications
- The Genomic Landscape of Pediatric Ewing Sarcoma
- (2014) B. D. Crompton et al. Cancer Discovery
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- A Comprehensive Mathematical Model for Three-Body Binding Equilibria
- (2013) Eugene F. Douglass et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties
- (2013) Michael P. Menden et al. PLoS One
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Use of Collateral Sensitivity Networks to Design Drug Cycling Protocols That Avoid Resistance Development
- (2013) L. Imamovic et al. Science Translational Medicine
- Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features
- (2012) Zhizhou Fang et al. ACS Chemical Biology
- A novel retinoblastoma therapy from genomic and epigenetic analyses
- (2012) Jinghui Zhang et al. NATURE
- Using transcriptome sequencing to identify mechanisms of drug action and resistance
- (2012) Sarah A Wacker et al. Nature Chemical Biology
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
- (2010) T. O'Hare et al. CLINICAL CANCER RESEARCH
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Ultra‐Deep Pyrosequencing of Hepatitis B Virus Quasispecies from Nucleoside and Nucleotide Reverse‐Transcriptase Inhibitor (NRTI)–Treated Patients and NRTI‐Naive Patients
- (2009) Severine Margeridon‐Thermet et al. JOURNAL OF INFECTIOUS DISEASES
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Mechanisms of drug combinations: interaction and network perspectives
- (2009) Jia Jia et al. NATURE REVIEWS DRUG DISCOVERY
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More